Roche paid $700 million upfront to co-develop and co-commercialize bexobrutideg, Nurix Therapeutics’ BTK protein degrader, in a deal that could reach $3 billion in total. The structure gives Roche 60% of development costs and all commercial rights outside the U.S.; Nurix keeps half of U.S. profits and co-commercializes domestically, which is the part that doesn’t look like a typical sell-the-company-and-go-home deal.
What Roche actually bought: a phase 3-ready asset pointed at Eli Lilly’s Jaypirca in chronic and small lymphocytic leukemia. Bexobrutideg degrades BTK proteins entirely rather than just blocking the kinase, stripping out both enzymatic and scaffolding functions. Bexobrutideg phase 1a data showed median progression-free survival of 22.1 months in heavily pretreated CLL patients. Lilly’s pivotal Jaypirca trial produced 14 months. Cross-trial comparisons carry caveats, but that spread is what $700 million upfront buys you.
The closest comparable in protein degradation is the Pfizer-Arvinas partnership from 2021, which paid $650 million upfront for ARV-471, a protein degrader targeting breast cancer. Roche matched that upfront and then stacked $2.3 billion more in milestones — a $3 billion ceiling that signals the clinical plan extends well beyond CLL. The roadmap includes neurology indications like multiple sclerosis and immunology work in chronic spontaneous urticaria, where Novartis and Sanofi are developing BTK inhibitors.
BeOne’s BGB-16673 degrader is running in three phase 3 trials. AbbVie has its own BTK degrader, ABBV-101, in phase 1. Even if bexobrutideg clears Jaypirca in CLL, Roche won’t own this class for long. At $3 billion, neurology and immunology aren’t optional.
— Diana Kowalski